

Online Supplemental Data

Systemic Review and Meta-analyses: Real-World Effectiveness of Direct-acting Antiviral Therapies in Chronic Hepatitis C Genotype 3 in Asia

Bin Wei*¹, Fanpu Ji*^{1,2,3}, Yee Hui Yeo¹, Eiichi Ogawa^{1,4}, Christopher D. Stave⁵, Shuangsoo Dang², Zongfang Li^{3,6}, Norihiro Furusyo⁴, Ramsey C. Cheung^{1,7}, Mindie H. Nguyen¹

Online Supplementary 1: Table S1 SVR12 of DAA therapies in Asia meta-analyses of real-world studies and global clinical trials in HCV GT3 patients	2
Online Supplementary 2: Table S2 Quality assessment of the included studies	3
Online Supplementary 3: Table S3 Sensitivity analyses by study setting, sample size and quality assessment score.....	4
Online Supplementary 4: Figure S1 Forest plot for sustained virologic response (SVR 12) in chronic hepatitis C genotype 3 patients treated with DAAs in Asia by regimens.....	5
Online Supplementary 5: Figure S2 Forest plot for sustained virologic response (SVR 12) in chronic hepatitis C genotype 3 patients treated with DAAs in Asia by treatment history.....	6
Online Supplementary 6: Figure S3 Forest plot for sustained virologic response (SVR 12) in chronic hepatitis C genotype 3 patients treated with DAAs in Asia by cirrhosis status and treatment history	7
Online Supplementary 7: Figure S4 Forest plot for sustained virologic response (SVR 12) in chronic hepatitis C genotype 3 patients treated with DAAs in Asia by country	8
Online Supplementary 8: Supplemental List 1: List of Asian countries and areas included in literature search based on PubMed MeSH term for Asia.....	9

Online Supplementary 1: Table S1 SVR12 of DAA therapies in Asia meta-analyses of real-world studies and global clinical trials in HCV GT3 patients

Study		Our study	VALENCE	BOSON	ALLY-3	Other network meta-analysis* (reference 40)
Study setting		Real-world practice	Clinical trial	Clinical trial	Clinical trial	RCTs; single-arm studies; observational cohorts
Patient No.	Total	4230	250	592 (GT2>3)	152	-
	Asian (%)	4230 (100%)	9 (4%)	80 (14%) (GT2>3)	7 (5%)	-
SVR12 by DAA Regimen	SOF+RBV for 16 weeks	-	-	71%	-	-
	SOF+RBV for 24 weeks	93.0%	-	84%	-	87% NC 56% LC
	SOF+RBV+PEG-IFN for 12 weeks	95.4%	-	93%	-	95% NC 78% LC
	DCV+SOF±RBV for 12 or 24 weeks	91.7%	-	-	89%	96% NC 80% LC
	LDV+SOF for 12 weeks	75.0%	-	-	-	-
SVR12 for GT3	Overall:	92.7%	85%	83%	89%	-
	NC	98.9%	91%	87%	96%	-
	LC	88.6%	68%	73%	63%	-
	TN	94.6%	-	86%	90%	-
	TE	94.0%	-	78%	86%	-

Note: * This study include regimens other than the five DAA regimens included in our meta-analysis

GT, genotype; DAA, Direct-acting antiviral; NC, non-cirrhosis; LC, liver cirrhosis; TN, treatment naïve; TE, treatment experienced; SVR, sustained virological response;

Online Supplementary 2: Table S2 Quality assessment of the included studies

First Author Published Year	Selection score (4 points)	Comparability score (2 points)	Outcome score (3 points)	Total score (9 points)
Abbas 2017	2	1	2	5
Akhter 2016	4	2	2	8
Capileno 2017	3	0	3	6
Farooqi 2016	3	0	0	3
Goel 2017	4	1	3	8
Hlaing 2017	3	1	3	7
Mehta 2016	3	2	3	8
Merta 2017	3	2	3	8
Sarwar 2017	2	0	2	4
Satsangi 2017	3	2	2	7
Shah 2016	2	2	2	6
Sidhu 2017	3	2	3	8
Sood 2017	4	2	1	7
Win 2016	2	0	1	3
Yousaf 2017	3	2	2	7


Note: Quality assessment performed by the developed Newcastle-Ottawa Scale for cohort studies (NOS).

Online Supplementary 3: Table S3 Sensitivity analyses by study setting, sample size and quality assessment score


Study characteristics	Number of studies	N	SVR12 estimate (95%CI)	I²
Study setting: Full-text publication	10	2435	91.7% (88.1% - 94.6%)	84.4%
Sample size: > 100 participants	9	3885	92.3% (87.3% - 96.1%)	95.6%
Quality assessment: Fair to High-quality studies (score ≥ 4)	13	4110	92.2% (88.1% - 95.6%)	93.7%

Note: Quality assessment performed by the Newcastle-Ottawa Scale for cohort studies to evaluate risk of bias; SVR 12, sustained virological response 12 weeks after the end of treatment


Online Supplementary 4: Figure S1 Forest plot for sustained virologic response (SVR 12) in chronic hepatitis C genotype 3 patients treated with DAAs in Asia by regimens




Online Supplementary 5: Figure S2 Forest plot for sustained virologic response (SVR 12) in chronic hepatitis C genotype 3 patients treated with DAAs in Asia by treatment history



Online Supplementary 6: Figure S3 Forest plot for sustained virologic response (SVR 12) in chronic hepatitis C genotype 3 patients treated with DAAs in Asia by cirrhosis status and treatment history



Online Supplementary 7: Figure S4 Forest plot for sustained virologic response (SVR 12) in chronic hepatitis C genotype 3 patients treated with DAAs in Asia by country



Online Supplementary 8: Supplemental List 1: List of Asian countries and areas included in literature search based on PubMed MeSH term for Asia

Asia Countries and Asia Areas

Asia, Central

- Kazakhstan
- Kyrgyzstan
- Tajikistan
- Turkmenistan
- Uzbekistan

Asia, Northern

- Siberia

Asia, Southeastern

- Borneo
- Brunei
- Cambodia
- Indonesia
- Laos
- Malaysia
- Mekong Valley
- Myanmar
- Philippines
- Singapore
- Thailand
- Timor-Leste
- Vietnam

Asia, Western

- Bangladesh
- Bhutan
- India
- Afghanistan
- Bahrain
- Iran
- Iraq
- Israel
- Jordan
- Kuwait
- Lebanon
- Oman
- Qatar
- Saudi Arabia
- Syria
- Turkey
- United Arab Emirates
- Yemen
- Nepal
- Pakistan
- Sri Lanka

Far East

- China
- Japan
- Korea
- Mongolia
- Taiwan